In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer

Triple-negative breast cancer (TNBC) lacks prognostic and predictive markers. Here, we use high-throughput phosphoproteomics to build a functional TNBC taxonomy. A cluster of 159 phosphosites is upregulated in relapsed cases of a training set (n = 34 patients), with 11 hyperactive kinases accounting...

Full description

Bibliographic Details
Authors: Zagorac, Ivana; Fernandez-Gaitero, Sara; Penning, Renske; Post, Harm; Bueno Verdejo, Maria Jose; Mouron, Silvana Andrea; Manso, Luis; Morente Gallego, Manuel M; Alonso, Soledad; Serra, Violeta; Muoz Peralta, Javier; Gomez Lopez, Gonzalo; Lopez-Acosta, Jose Francisco; Jimenez-Renard, Veronica; Gris-Oliver, Albert; Al-Shahrour, Fatima; Piñeiro-Yañez, Elena; Montoya-Suarez, Jose Luis; Apala, Juan V; Moreno-Torres, Amalia; Colomer, Ramon; Dopazo, Ana; Heck, Albert J R; Altelaar, Maarten; Quintela Fandino, Miguel Angel
Format: Article
Publication date:2018
Country:España
Institution:Instituto de Salud Carlos III (ISCIII)
Repository:Repisalud
Language:English
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/6527
Online Access:http://hdl.handle.net/20.500.12105/6527
Access Level:Open access
Description
Summary:Triple-negative breast cancer (TNBC) lacks prognostic and predictive markers. Here, we use high-throughput phosphoproteomics to build a functional TNBC taxonomy. A cluster of 159 phosphosites is upregulated in relapsed cases of a training set (n = 34 patients), with 11 hyperactive kinases accounting for this phosphoprofile. A mass-spectrometry-to-immunohistochemistry translation step, assessing 2 independent validation sets, reveals 6 kinases with preserved independent prognostic value. The kinases split the validation set into two patterns: one without hyperactive kinases being associated with a >90% relapse-free rate, and the other one showing ≥1 hyperactive kinase and being associated with an up to 9.5-fold higher relapse risk. Each kinase pattern encompasses different mutational patterns, simplifying mutation-based taxonomy. Drug regimens designed based on these 6 kinases show promising antitumour activity in TNBC cell lines and patient-derived xenografts. In summary, the present study elucidates phosphosites and kinases implicated in TNBC and suggests a target-based clinical classification system for TNBC.